In the RA non-FM, but not in the RA-FM group, GS and PD-US7 correlated with SJC (r=0.44, r=0.47, r=0.57, r=0.46, and PD synovitis negatively correlated with the "joint count" criteria (r=-0.44, p=0.015 and higher prevalence of sarcopenia than healthy individuals. A prospective observational study (CHIKARA study, registration number: UMIN000023744) was started to clarify the influence of changes in disease activity for sarcopenia. Objectives: We investigated the relationship between sarcopenia and disease activity at baseline in patients with RA. Methods: We analyzed baseline data from the CHIKARA study (Correlation research of sarcopenia, skeletal muscle and disease activity in rheumatoid arthritis). Sarcopenia was diagnosed using the criteria of the Asia Working Group on Sarcopenia 2 . Muscle mass, body fat mass, total body water, bone mass, and basal metabolic rate were measured using a body composition analyzer (MC-780A; TANITA, Tokyo, Japan). We investigated correlations between sarcopenia and disease activity (DAS28-ESR, SDAI, physical function (HAQ), and laboratory data using uni-and multivariate analyses. Results: Participants comprised 100 patients with RA (females, 78%; mean age, 66.1 years). Mean disease duration was 5.5 years, DAS28-ESR was 3.55, and the percentage of subjects with sarcopenia was 28%. Table 1 shows risk factors for sarcopenia. Sarcopenia correlated with weight, body mass index (BMI), body fat mass, muscle mass, basal metabolic rate, Steinbrocker stage, CRP bone mass, and matrix metalloprotease (MMP)-3 on univariate analysis. Glucocorticoid dosage, rheumatoid factor, and anti-CCP antibody showed no correlation with sarcopenia. BMI, body fat mass, and MMP-3 were identified as independent risk factors on multivariate analysis. MMP-3 over 90.7 ng/ml was a risk factor for sarcopenia by ROC curve analysis (odds ratio, 3.09; p=0.023). Background: One of the most effective strategies to prevent infections is vaccination, especially in patients treated with biologics and immunosuppressive (IS) agents. Nevertheless, the effectiveness of the resulting immune response in these patients has been questioned. Objectives: To perform a systematic literature review aiming to assess evidence available regarding immune response efficiency (IRE) and the ideal schedule for vaccination in RA and SpA patients treated with Methotrexate (MTX), TNF inhibitors (TNFi), anti-CD20 (rituximab, RTX), anti-CTLA4 (abatacept, ABA) or anti-IL6 (tocilizumab, TCZ). Methods: A systematic literature review was conducted by searching in PubMed all studies with the MeSH terms "[Rheumatoïd Arthritis" OR "Spondyloarthritis"] AND ["vaccination" OR "vaccines"] AND ["Methotrexate" OR "Abatacept" OR "Tocilizumab" OR "Rituximab" OR "Adalimumab" OR "Certolizumab" OR "Etanercept" OR "Golimumab" OR "Infliximab"], with no limitation regarding time of publication. Only studies evaluating the IRE were included. Case reports, general reviews and meta-analysis were excluded. Results: After exclusion criteria, 35 studies (out of 60 studies retrieved) assessing IRE in RA or SpA patients were selected, under MTX (n=35), TNFi (n=18), RTX (n=8), ABA (n=4) or TCZ (n=5). The studied vaccines were mostly the trivalent seasonal Influenza (n=20), the anti-pneumococcal vaccine (n=16), and few studies regarding the tetanus toxoid vaccine (TTV) (n=2), Hepatitis A vaccine (n=1) and accidental revaccination against yellow fever (n=2). Most studies (32/35) evaluated the IRE using the antibody (Ab) titer. When studying the anti-pneumococcal and influenza vaccination, the primary outcome was mainly the seroresponse 3 to 6 weeks after vaccination (i.e. Ab ratio post/pre-vaccine) but some studies (15/35) also assessed the seroprotection rate (i.e. patients with an effective titer of protective Ab), and some (3/35) the effectiveness of seroresponse using the opsonization index rate. Regarding the anti-pneumococcal and influenza vaccination, MTX, RTX, and ABA were reported to impair the immune response; neither TNFi nor TCZ were shown to decrease seroresponse.
